10 results on '"Xia, Mingfeng"'
Search Results
2. Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism
- Author
-
Yan, Hongmei, Wu, Weiyun, Chang, Xinxia, Xia, Mingfeng, Ma, Sicheng, Wang, Liu, and Gao, Jian
- Published
- 2021
- Full Text
- View/download PDF
3. FoxO3 regulates hepatic triglyceride metabolism via modulation of the expression of sterol regulatory-element binding protein 1c
- Author
-
Wang, Liu, Zhu, Xiaopeng, Sun, Xiaoyang, Yang, Xinyu, Chang, Xinxia, Xia, Mingfeng, Lu, Yan, Xia, Pu, Yan, Hongmei, Bian, Hua, and Gao, Xin
- Published
- 2019
- Full Text
- View/download PDF
4. Metformin attenuates triglyceride accumulation in HepG2 cells through decreasing stearyl-coenzyme A desaturase 1 expression
- Author
-
Zhu, Xiaopeng, Yan, Hongmei, Xia, Mingfeng, Chang, Xinxia, Xu, Xi, Wang, Liu, Sun, Xiaoyang, Lu, Yan, Bian, Hua, Li, Xiaoying, and Gao, Xin
- Published
- 2018
- Full Text
- View/download PDF
5. A novel model for detecting advanced fibrosis in patients with nonalcoholic fatty liver disease.
- Author
-
Yang, Xinyu, Xia, Mingfeng, Chang, Xinxia, Zhu, Xiaopeng, Sun, Xiaoyang, Yang, Yinqiu, Wang, Liu, Liu, Qiling, Zhang, Yuying, Xu, Yanlan, Lin, Huandong, Liu, Lin, Yao, Xiuzhong, Hu, Xiqi, Gao, Jian, Yan, Hongmei, Gao, Xin, and Bian, Hua
- Subjects
NON-alcoholic fatty liver disease ,LIVER histology ,FIBROSIS ,MULTIPLE regression analysis ,RECEIVER operating characteristic curves ,BLOOD sugar - Abstract
Aims: The study aimed to develop a novel noninvasive model to detect advanced fibrosis based on routinely available clinical and laboratory tests. Materials and Methods: A total of 309 patients who underwent liver biopsy were randomly divided into the estimation group (n = 201) and validation group (n = 108). The model was developed using multiple regression analysis in the estimation group and further verified in the validation group. Diagnostic accuracy was evaluated using the receiver operating characteristic (ROC) curve. Results: The model was named NAFLD Fibrosis Index (NFI): −10.844 + 0.046 × age − 0.01 × platelet count + 0.19 × 2h postprandial plasma glucose (PG) + 0.294 × conjugated bilirubin − 0.015 × ALT + 0.039 × AST + 0.109 × total iron binding capacity −0.033 × parathyroid hormone (PTH). The area under the ROC curve (AUC) of NFI was 0.86 (95% CI: 0.79–0.93, p < 0.001) in the estimation group and 0.80 (95% CI: 0.69–0.91, p < 0.001) in the validation group, higher than NFS, FIB4, APRI, and BARD, and similar to FibroScan (NFI AUC = 0.77, 95% CI: 0.66–0.89, p = 0.001 vs. FibroScan AUC = 0.76, 95% CI: 0.62–0.90, p = 0.002). By applying the low cut‐off value (−2.756), advanced fibrosis could be excluded among 49.3% and 48% of patients in the estimation group (sensitivity: 93.1%, NPV: 97.9%, specificity: 55.2%, and PPV: 26.0%) and validation group (sensitivity: 81.3%, NPV: 94.2%, specificity: 53.3%, and PPV: 23.2%), respectively, allowing them to avoid liver biopsy. Conclusions: The study has established a novel model for advanced fibrosis, the diagnostic accuracy of which is superior to the current clinical scoring systems and is similar to FibroScan. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes.
- Author
-
Liu, Lin, Yan, Hongmei, Xia, MingFeng, Zhao, Lin, Lv, Minzhi, Zhao, Naiqin, Rao, Shengxiang, Yao, Xiuzhong, Wu, Weiyun, Pan, Baishen, Bian, Hua, and Gao, Xin
- Subjects
FATTY liver ,TYPE 2 diabetes ,BLOOD sugar ,NUCLEAR magnetic resonance spectroscopy ,INSULIN ,BLOOD sugar analysis ,RESEARCH ,RESEARCH methodology ,HYPOGLYCEMIC agents ,PROGNOSIS ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,RANDOMIZED controlled trials ,RESEARCH funding ,STATISTICAL sampling ,LONGITUDINAL method ,DISEASE complications - Abstract
Background: The aim of this study was to investigate the efficacy of exenatide and insulin glargine in patients with newly diagnosed type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD).Methods: We performed a 24-week randomized controlled multicentre clinical trial. Seventy-six patients were randomly assigned 1:1 to receive exenatide or insulin glargine treatment. The endpoints included changes in liver fat content (LFC), visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) measured by magnetic resonance spectroscopy, blood glucose, liver enzymes, lipid profile, body weight, and Fibrosis-4 index (FIB-4).Results: LFC, VAT, SAT, and FIB-4 were significantly reduced after exenatide treatment (ΔLFC, -17.55 ± 12.93%; ΔVAT, -43.57 ± 68.20 cm2 ; ΔSAT, -28.44 ± 51.48 cm2 ; ΔFIB-4, -0.10 ± 0.26; all P < .05). In comparison, only LFC (ΔLFC, -10.49 ± 11.38%; P < .05), and not VAT, SAT, or FIB-4 index (all P > .05), was reduced after insulin glargine treatment. Moreover, exenatide treatment resulted in greater reductions in alanine transaminase (ALT), aspartate transaminase (AST), and gamma glutamyl transpeptidase (GGT) than insulin glargine (P < 0.05). The body weight, waist circumference, postprandial plasma glucose, and low-density lipoprotein cholesterol (LDL-C) in the exenatide group also presented greater reductions than the insulin glargine group (P < .05). The proportion of adverse events were comparable between the two groups.Conclusion: Both exenatide and insulin glargine reduced LFC in patients with drug-naive T2DM and NAFLD; however, exenatide showed greater reductions in body weight, visceral fat area, liver enzymes, FIB-4, postprandial plasma glucose, and LDL-C. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
7. Postprandial glucose is correlated with an increasing risk of liver fibrosis in Chinese patients with nonalcoholic fatty liver disease.
- Author
-
Chang, Xinxia, Bian, Hua, Xia, Mingfeng, Zhu, Xiaopeng, Sun, Xiaoyang, Yang, Xinyu, Gao, Jian, Lin, Huandong, Yan, Hongmei, and Gao, Xin
- Subjects
HEPATIC fibrosis ,FATTY liver ,NON-alcoholic fatty liver disease ,CHINESE people ,TYPE 2 diabetes ,BLOOD sugar - Abstract
Type 2 diabetes (T2DM) is closely related to nonalcoholic fatty liver disease (NAFLD) and is an important risk factor for the progression of liver fibrosis, but the role of 2-h postprandial blood glucose (PPG) as a biomarker in this process remains unclear. This study was designed to investigate the relationship between PPG and liver fibrosis in Chinese NAFLD populations with or without T2DM. This study included three independent NAFLD populations: 1) 618 inpatients with T2DM or pre-diabetes, 2) 255 patients with T2DM or pre-diabetes who underwent liver biopsy, and 3) a prospective community-based cohort without diabetes who completed a median of 4.22 years follow-up. The degree of liver fibrosis was assessed by liver fibrosis stage in subjects with a liver biopsy, and by NAFLD fibrosis score (NFS) in subjects without liver biopsy. In the first population, PPG {OR 0.02, [95% CI (0.01–0.03)], P< 0.001} was positively correlated with NFS. In the second population, an increasing PPG was associated with increase in the proportion of advanced liver fibrosis (P = 0.012). Multivariate line regression revealed that PPG {OR 0.03 [95% CI (0.00–0.06)], P = 0.049}was positively associated with liver fibrosis stages. In the third population, PPG {OR 0.103, [95% CI (0.011–0.194) P = 0.028} at baseline was positively associated with NFS at follow-up. Furthermore, changes in PPG were significantly associated with NFS change after follow-up. We did not find a similar association between fasting glucose or HbA1c and liver fibrosis. PPG was independently associated with the severity of liver fibrosis in the Chinese NAFLD population. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease.
- Author
-
Xinxia Chang, Zhe Wang, Jinlan Zhang, Hongmei Yan, Hua Bian, Mingfeng Xia, Huandong Lin, Jiandong Jiang, Xin Gao, Chang, Xinxia, Wang, Zhe, Zhang, Jinlan, Yan, Hongmei, Bian, Hua, Xia, Mingfeng, Lin, Huandong, Jiang, Jiandong, and Gao, Xin
- Subjects
BERBERINE ,FATTY liver ,THERAPEUTICS ,SPHINGOLIPIDS ,CERAMIDES ,ALKALOIDS ,LIPID metabolism ,LIQUID chromatography-mass spectrometry ,METABOLITES ,THERAPEUTIC use of alkaloids ,LIPID analysis ,BIOCHEMISTRY ,COMPARATIVE studies ,DISCRIMINANT analysis ,ENERGY metabolism ,GENETIC disorders ,LIPID metabolism disorders ,LIVER ,RESEARCH methodology ,MEDICAL cooperation ,REGRESSION analysis ,RESEARCH ,EVALUATION research ,LIFESTYLES ,RANDOMIZED controlled trials - Abstract
Background: We recently demonstrated a positive effect of berberine on nonalcoholic fatty liver disease patients after 16 weeks of treatment by comparing mere lifestyle intervention in type 2 diabetes patients with berberine treatment, which decreased the content of hepatic fat. However, the potential mechanisms of the clinical effects are unclear. We used a lipidomic approach to characterize the state of lipid metabolism as reflected in the circulation of subjects with nonalcoholic fatty liver disease (NAFLD) before and after berberine treatment.Methods: Liquid chromatography-mass spectrometry evaluated the various lipid metabolites in serum samples obtained from the participants (41 patients in the berberine group and 39 patients in the mere lifestyle intervention group) before and after treatment.Results: A total of 256 serum lipid molecular species were identified and quantified. Both treatments regulated various types of lipids in metabolic pathways, such as free fatty acids, phosphoglycerides and glycerides, in metabolic pathways, but berberine induced a substantially greater change in serum lipid species compared with mere lifestyle intervention after treatment. Berberine also caused obvious differences on ceramides. Berberine treatment markedly decreased serum levels of ceramide and ceramide-1-phosphate.Conclusions: Berberine altered circulating ceramides, which may underlie the improvement in fatty liver disease. ClinicalTrials.gov NCT00633282, Registered March 3, 2008. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
9. DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing.
- Author
-
Li, Yufeng, Xu, Junyu, Lu, Yuting, Bian, Hua, Yang, Lin, Wu, Honghong, Zhang, Xinwen, Zhang, Beilei, Xiong, Maoqian, Chang, Yafei, Tang, Jie, Yang, Fan, Zhao, Lei, Li, Jing, Gao, Xin, Xia, Mingfeng, Tan, Minjia, and Li, Jingya
- Abstract
Nonalcoholic steatohepatitis (NASH) is an advanced stage of nonalcoholic fatty liver disease (NAFLD) with serious consequences that currently lacks approved pharmacological therapies. Recent studies suggest the close relationship between the pathogenesis of NAFLD and the dysregulation of RNA splicing machinery. Here, we reveal death-associated protein kinase-related apoptosis-inducing kinase-2 (DRAK2) is markedly upregulated in the livers of both NAFLD/NASH patients and NAFLD/NASH diet-fed mice. Hepatic deletion of DRAK2 suppresses the progression of hepatic steatosis to NASH. Comprehensive analyses of the phosphoproteome and transcriptome indicated a crucial role of DRAK2 in RNA splicing and identified the splicing factor SRSF6 as a direct binding protein of DRAK2. Further studies demonstrated that binding to DRAK2 inhibits SRSF6 phosphorylation by the SRSF kinase SRPK1 and regulates alternative splicing of mitochondrial function-related genes. In conclusion, our findings reveal an indispensable role of DRAK2 in NAFLD/NASH and offer a potential therapeutic target for this disease. [Display omitted] • DRAK2 is markedly upregulated in the livers of both patients and mice with NAFLD/NASH • DRAK2 regulates RNA alternative splicing through SRPK1-mediated SRSF6 phosphorylation • DRAK2 disturbs mitochondrial function in hepatic steatosis via RNA splicing machinery • Suppression of DRAK2 in hepatocytes ameliorates NAFLD/NASH progression Li et al. identified DRAK2 as a novel and essential regulator of nonalcoholic steatohepatitis (NASH). DRAK2 promotes NASH via directly interacting with SRSF6 to inhibit its phosphorylation by SRPK1 and regulate alternative splicing of mitochondrial function-related genes. This functional mechanism of DRAK2 offers a potential therapeutic target for this disease. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
- Author
-
Zhu, Xiaopeng, Bian, Hua, Wang, Liu, Sun, Xiaoyang, Xu, Xi, Yan, Hongmei, Xia, Mingfeng, Chang, Xinxia, Lu, Yan, Li, Yu, Xia, Pu, Li, Xiaoying, and Gao, Xin
- Subjects
- *
BERBERINE , *FATTY degeneration , *MESSENGER RNA , *FATTY liver , *HIGH-fat diet , *TRIPTOLIDE - Abstract
Berberine (BBR), a natural compound extracted from Chinese herb, has been shown to effectively attenuate nonalcoholic fatty liver disease (NAFLD) in clinic. However, the mechanism underlying the effect of BBR is not fully understood. Stearyl-coenzyme A desaturase 1 (SCD1) mediates lipid metabolism in liver. Therefore, we hypothesized that SCD1 mediated the beneficial effect of BBR on NAFLD. The expression of SCD1 was measured in the liver of NAFLD patients and ob/ob mice. The effect of BBR on NAFLD was evaluated in C57BL/6 J mice on high fat diet (HFD). The effect of BBR was also investigated in HepG2 and AML12 cells exposed to high glucose and palmitic acid. Oil red O staining was performed to detect triglyceride (TG) level. Quantitative real-time polymerase chain reaction and Western blot were used to detect the messenger ribonucleic acid (mRNA) and protein expression of target genes. The activity of SCD1 promoter was measured by dual-luciferase reporter assay. The expression of SCD1 was increased in the liver of NAFLD patients and ob/ob mice. BBR reduced hepatic TG accumulation and decreased the expressions of hepatic SCD1 and other TG synthesis related genes both in vivo and in vitro. Knockdown of SCD1 expression mimicked the effect of BBR decreasing TG level in steatotic hepatocytes, whereas overexpression of SCD1 attenuated the effect of BBR. Mechanistically, BBR promoted the phosphorylation of AMP-activated protein kinase (AMPK) and sterol regulatory element-binding protein-1c (SREBP-1c) in HepG2 cells and the liver of HFD-fed mice. Activation of the AMPK-SREBP-1c pathway and sterol regulatory element (SRE) motif in SCD1 promoter (−920/-550) was responsible for the BBR-induced suppression of SCD1. BBR reduces liver TG synthesis and attenuates hepatic steatosis through the activation of AMPK-SREBP-1c-SCD1 pathway. Image 1 • The expression of SCD1 is increased in the liver of NAFLD patients and mice with fatty liver compared with control group. • Berberine reduces the expression of SCD1 in the liver and attenuates hepatic steatosis. • AMPK-SREBP-1c-SCD1 pathway mediates the effect of berberine on hepatic steatosis. • This study identifies a novel mechanism for berberine in the treatment of steatosis, which may promote its application. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.